Stability-Indicating HPLC Method for the Simultaneous Determination of Valsartan and Ezetimibe in Pharmaceuticals
Purpose: To develop a simple, accurate, sensitive, precise and robust reverse-phase HPLC stabilityindicating method for the simultaneous estimation of valsartan and ezetimibe in combined tablet formulation.
Methods: A stability indicating method for the simultaneous estimation of valsartan and ezetimibe in combined tablet formulation using a RP-HPLC was developed and validated as per ICH guidelines using a symmetry C18 column with a mobile phase comprising phosphate buffer and acetonitrile (58:42 v/v, pH 3.15) with a flow rate of 0.8 mL/min at 230 nm. Stress degradation studies were performed in acidic, alkaline, oxidation and photolysis conditions to demonstrate the stability-indicating power of the method.
Results: The contents of valsartan and ezetimibe were in the range of 99.77 ± 0.10 and 99.30 ± 0.43 % in the marketed formulation, 99.77 ± 0.08 and 99.29 ± 0.38 for the test formulation, respectively. The correlation coefficient for both valsartan and ezetimibe was 0.999 and recovery was in the range of 98 – 102 %. The limit of detection (LOD) was 0.2 and 0.3 μg/mL for valsartan and ezetimibe, respectively, while limit of quantification (LOQ) was 1 μg/mL for both valsartan and ezetimibe, respectively.
Conclusion: The proposed method is simple, precise, accurate, reproducible, specific and reproducible used for the quantitative determination of valsartan and ezetimibe in bulk and dosage formulations.
Keywords: Valsartan, Ezetimibe, Validation, Stability-indicating, Pharmaceuticals
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.